Functional studies have demonstrated that two specific domains of the c-Myc protein are essential for cell transformation: the C- terminal 100 amino acids which encompass the DNA binding basic/helix-loop- helix/leucine zipper region (B/HLH/LZ), and a small 20 amino acid segment from the N-terminus (called Myc homology box II of MbII) that is conserved in all members of the Myc family of proteins. This project will address the function of MbII domain of c-Myc through an analysis of the nuclear proteins that bind to this region and which are also essential for the transforming activity of the oncoprotein. Previous studies have showed that dominant interfering alleles of the c-Myc protein form protein complex that are dependent on the integrity of MbII and hence correlate with nuclear factors that may be essential for c-Myc function.
The specific aims are as follows: I. Analyze the function of a novel protein called TR-AP that binds to the essential MBII region of the c-Myc oncoprotein in vivo. Genetic evidence suggests that TR-AP is required for the transforming activity of c-Myc and hence is a critical effector of c-Myc function. It is hypothesized that the c-Myc/Max heterodimer recruits TR-AP to specific chromosomal sites to alter gene expression and/or chromatin structure. II. Analyze the function of the yeast homologue of human TR-AP (called TRA1) to determine the essential role that this gene plays in growth. Yeast strains deficient in TRA1 will then be used to conduct a genetic screen to identify human and yeast genes that can complement a loss-of- function mutation in TR-AP. These experiments offer a novel genetic approach toward an understanding of c-Myc function. III. Purify and clone a nuclear protein that can bind tightly to the N-Myc oncoprotein and which appear to bind specifically to N-Myc but not c-Myc. He will also conduct a systematic mapping of the functional domains of the N-Myc protein to correlate important regions with nuclear factor interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055248-11
Application #
6512722
Study Section
Molecular Cytology Study Section (CTY)
Program Officer
Perry, Mary Ellen
Project Start
1992-08-12
Project End
2003-08-31
Budget Start
2002-03-01
Budget End
2003-08-31
Support Year
11
Fiscal Year
2002
Total Cost
$437,744
Indirect Cost
Name
Princeton University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
002484665
City
Princeton
State
NJ
Country
United States
Zip Code
08544
Smits, Nicole C; Kobayashi, Takashi; Srivastava, Pratyaksh K et al. (2017) HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. Matrix Biol 63:69-90
Weyburne, Emily S; Wilkins, Owen M; Sha, Zhe et al. (2017) Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation. Cell Chem Biol 24:218-230
Posternak, Valeriya; Ung, Matthew H; Cheng, Chao et al. (2017) MYC Mediates mRNA Cap Methylation of Canonical Wnt/?-Catenin Signaling Transcripts By Recruiting CDK7 and RNA Methyltransferase. Mol Cancer Res 15:213-224
Posternak, Valeriya; Cole, Michael D (2016) Strategically targeting MYC in cancer. F1000Res 5:
Cowling, V H; Turner, S A; Cole, M D (2014) Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis. Oncogene 33:3519-27
Cole, Michael D (2014) MYC association with cancer risk and a new model of MYC-mediated repression. Cold Spring Harb Perspect Med 4:a014316
Kaur, Mandeep; Cole, Michael D (2013) MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res 73:695-705
Doe, Megan R; Ascano, Janice M; Kaur, Mandeep et al. (2012) Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res 72:949-57
Savino, Mauro; Annibali, Daniela; Carucci, Nicoletta et al. (2011) The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 6:e22284
Choi, Seung H; Wright, Jason B; Gerber, Scott A et al. (2010) Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev 24:1236-41

Showing the most recent 10 out of 21 publications